Candel Therapeutics to Present at the SITC 2026 Annual Meeting
Key Highlights
- ➤Candel Therapeutics (CADL) will present NSCLC data at SITC 2026.
- ➤NSCLC poster links aglatimagene besadenovec plus valacyclovir to improved survival.
- ➤Glioblastoma poster examines linoserpaturev combined with VEGF blockade.
- ➤SITC presentations scheduled November 6 and November 7, 2026.
- ➤Linoserpaturev previously received FDA Fast Track and Orphan Drug Designations.
Expert Statements
Caroline Duault, Senior Research Scientist, Stanford University
“Multi-omics analyses reveal intratumoral and systemic immune activation to aglatimagene besadenovec+valacyclovir related to improved survival in patients with progressive NSCLC despite ICI treatment”
Francesca Barone, Chief Scientific Officer, Candel Therapeutics
“Combining linoserpaturev with Vascular Endothelial Growth Factor (VEGF) blockade to overcome hypoxia-associated immune suppression in glioblastoma”
NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical and mechanistic findings from its phase 1b clinical trial of linoserpaturev in recurrent glioblastoma, through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting, taking place November 4-8, 2026 in Phoenix, Arizona.
Title: Multi-omics analyses reveal intratumoral and systemic immune activation to aglatimagene besadenovec+valacyclovir related to improved survival in patients with progressive NSCLC despite ICI treatment
Get started
Create a free account to read the full story.